BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 31636099)

  • 21. Protein kinase A inhibition of macrophage maturation is accompanied by an increase in DNA methylation of the colony-stimulating factor 1 receptor gene.
    Zasłona Z; Scruggs AM; Peters-Golden M; Huang SK
    Immunology; 2016 Oct; 149(2):225-37. PubMed ID: 27353657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLX3397, a CSF1 receptor inhibitor, limits allotransplantation-induced vascular remodelling.
    Almonte VM; Uriyanghai U; Egaña-Gorroño L; Parikh D; Oliveira-Paula GH; Zhang J; Jayakumar S; Riascos-Bernal DF; Sibinga NES
    Cardiovasc Res; 2022 Sep; 118(12):2718-2731. PubMed ID: 34478521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage colony-stimulating factor-, granulocyte-macrophage colony-stimulating factor-, or IL-3-dependent survival of macrophages, but not proliferation, requires the expression of p21(Waf1) through the phosphatidylinositol 3-kinase/Akt pathway.
    Comalada M; Xaus J; Sánchez E; Valledor AF; Celada A
    Eur J Immunol; 2004 Aug; 34(8):2257-67. PubMed ID: 15259023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. iRhom2 regulates CSF1R cell surface expression and non-steady state myelopoiesis in mice.
    Qing X; Rogers L; Mortha A; Lavin Y; Redecha P; Issuree PD; Maretzky T; Merad M; McIlwain D; Mak TW; Overall CM; Blobel CP; Salmon JE
    Eur J Immunol; 2016 Dec; 46(12):2737-2748. PubMed ID: 27601030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways.
    Uemura Y; Kobayashi M; Nakata H; Kubota T; Bandobashi K; Saito T; Taguchi H
    Int J Mol Med; 2006 Aug; 18(2):365-73. PubMed ID: 16820947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
    Liu YQ; Wang YN; Lu XY; Tong LJ; Li Y; Zhang T; Xun QJ; Feng F; Chen YZ; Su Y; Shen YY; Chen Y; Geng MY; Ding K; Li YL; Xie H; Ding J
    Acta Pharmacol Sin; 2018 Nov; 39(11):1768-1776. PubMed ID: 29968849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFβ in claudin-low breast tumor cells.
    Patsialou A; Wang Y; Pignatelli J; Chen X; Entenberg D; Oktay M; Condeelis JS
    Oncogene; 2015 May; 34(21):2721-31. PubMed ID: 25088194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF1R signaling is a regulator of pathogenesis in progressive MS.
    Hagan N; Kane JL; Grover D; Woodworth L; Madore C; Saleh J; Sancho J; Liu J; Li Y; Proto J; Zelic M; Mahan A; Kothe M; Scholte AA; Fitzgerald M; Gisevius B; Haghikia A; Butovsky O; Ofengeim D
    Cell Death Dis; 2020 Oct; 11(10):904. PubMed ID: 33097690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Csf1r or Mer inhibition delays liver regeneration via suppression of Kupffer cells.
    Santamaria-Barria JA; Zeng S; Greer JB; Beckman MJ; Seifert AM; Cohen NA; Zhang JQ; Crawley MH; Green BL; Loo JK; Maltbaek JH; DeMatteo RP
    PLoS One; 2019; 14(5):e0216275. PubMed ID: 31042769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Papin A; Tessoulin B; Bellanger C; Moreau A; Le Bris Y; Maisonneuve H; Moreau P; Touzeau C; Amiot M; Pellat-Deceunynck C; Le Gouill S; Chiron D
    Leukemia; 2019 Oct; 33(10):2442-2453. PubMed ID: 30940906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.
    Han S; Zhen W; Guo T; Zou J; Li F
    J Exp Clin Cancer Res; 2020 Oct; 39(1):218. PubMed ID: 33059737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo.
    Liu Y; Given KS; Dickson EL; Owens GP; Macklin WB; Bennett JL
    Exp Neurol; 2019 Aug; 318():32-41. PubMed ID: 31029597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Transgenic Line That Reports CSF1R Protein Expression Provides a Definitive Marker for the Mouse Mononuclear Phagocyte System.
    Grabert K; Sehgal A; Irvine KM; Wollscheid-Lengeling E; Ozdemir DD; Stables J; Luke GA; Ryan MD; Adamson A; Humphreys NE; Sandrock CJ; Rojo R; Verkasalo VA; Mueller W; Hohenstein P; Pettit AR; Pridans C; Hume DA
    J Immunol; 2020 Dec; 205(11):3154-3166. PubMed ID: 33139489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The c.1085A>G Genetic Variant of
    Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
    Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
    [No Abstract]   [Full Text] [Related]  

  • 40. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
    Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
    J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.